Intensity modulated radiation therapy (IMRT) for the treatment of unicentric Castlemans disease: a case report and review of the use of radiotherapy in the literature

Castleman B, Iverson L, Menendez VP. Localized mediastinal lymphnode hyperplasia resembling thymoma. Cancer 1956; 9: 822-30.10.1002/1097-0142(195607/08)9:4<822::AID-CNCR2820090430>3.0.CO;2-4Search in Google Scholar

Gaba AR, Stein RS, Sweet DL, Variakojis D. Multicentric giant lymph node hyperplasia. Am J Clin Pathol 1978; 69: 86-90.10.1093/ajcp/69.1.86Search in Google Scholar

Soulier J, Grollet L, Oksenhendler E, Miclea JM, Cacoub P, Baruchel A, et al. Molecular analysis of clonality in Castleman's disease. Blood 1995; 86: 1131-8.10.1182/blood.V86.3.1131.1131Search in Google Scholar

Soulier J, Grollet L, Oksenhendler E, Cacoub P, Cazals-Hatem D, Babinet P, et al. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease. Blood 1995; 86: 1276-80.10.1182/blood.V86.4.1276.bloodjournal8641276Search in Google Scholar

Gessain A, Sudaka A, Brière J, Fouchard N, Nicola MA, Rio B, et al. Kaposi sarcoma-associated herpes-like virus (human herpesvirus type 8) DNA sequences in multicentric Castleman's disease: is there any relevant association in non-human immunodeficiency virus-infected patients? Blood 1996; 87: 414-6.10.1182/blood.V87.1.414.414Search in Google Scholar

Herrada J, Cabanillas F, Rice L, Manning J, Pugh W. The clinical behavior of localized and multicentric Castleman disease. Ann Intern Med 1998; 128: 657-62.10.7326/0003-4819-128-8-199804150-00010Search in Google Scholar

Casper C. The aetiology and management of Castleman disease at 50 years: translating pathophysiology to patient care. Br J Haematol 2005; 129: 3-17.10.1111/j.1365-2141.2004.05311.xSearch in Google Scholar

Seco JL, Velasco F, Manuel JS, Serrano SR, Tomas L, Velasco A. Retroperitoneal Castleman's disease. Surgery 1992; 112: 850-5.Search in Google Scholar

McCarty MJ, Vukelja SJ, Banks PM, Weiss RB. Angiofollicular lymph node hyperplasia (Castleman's disease). Cancer Treat Rev 1995; 21: 291-310.10.1016/0305-7372(95)90034-9Search in Google Scholar

Shahidi H, Myers JL, Kvale PA. Castleman's disease. Mayo Clin Proc 1995; 70: 969-77.10.4065/70.10.969Search in Google Scholar

Neuhof D, Debus J. Outcome and late complications of radiotherapy in patients with unicentric Castleman disease. Acta Oncol 2006; 45: 1126-31.10.1080/02841860600812701Search in Google Scholar

Chronowski GM, Ha CS, Wilder RB, Cabanillas F, Manning J, Cox JD. Treatment of unicentric and multicentric Castleman disease and the role of radiotherapy. Cancer 2001; 92: 670-6.10.1002/1097-0142(20010801)92:3<670::AID-CNCR1369>3.0.CO;2-QSearch in Google Scholar

Bowne WB, Lewis JJ, Filippa DA, Niesvizky R, Brooks AD, Burt ME, et al. The management of unicentric and multicentric Castleman's disease: a report of 16 cases and a review of the literature. Cancer 1999; 85: 706-17.10.1002/(SICI)1097-0142(19990201)85:3<706::AID-CNCR21>3.0.CO;2-7Search in Google Scholar

de Vries IA, van Acht MM, Demeyere TB, Lybeert ML, de Zoete JP, Nieuwenhuijzen GA. Neoadjuvant radiotherapy of primary irresectable unicentric Castleman's disease: a case report and review of the literature. Radiat Oncol 2010; 5: 7.10.1186/1748-717X-5-7Search in Google Scholar

Peterson BA, Frizzera G. Multicentric Castleman's disease. Semin Oncol 1993; 20: 636-47.Search in Google Scholar

Keller AR, Hochholzer L, Castleman B. Hyaline-vascular and plasma-cell types of giant lymph node hyperplasia of the mediastinum and other locations. Cancer 1972; 29: 670-83.10.1002/1097-0142(197203)29:3<670::AID-CNCR2820290321>3.0.CO;2-#Search in Google Scholar

Ye B, Gao SG, Li W, Yang LH, Zhao SH, Ma K, et al. A retrospective study of unicentric and multicentric Castleman's disease: a report of 52 patients. Med Oncol 2010; 27: 1171-8.10.1007/s12032-009-9355-0Search in Google Scholar

Lin CY, Chang YL. Castleman's disease in the head and neck region: Meta-analysis of reported cases in Taiwan and literature review. J Formos Med Assoc 2010; 109: 913-20.10.1016/S0929-6646(10)60139-8Search in Google Scholar

Paumier A, Ghalibafian M, Beaudre A, Ferreira I, Pichenot C, Messai T, et al. Involved-node radiotherapy and modern radiation treatment techniques in patients with Hodgkin lymphoma. Int J Radiat Oncol Biol Phys 2011; 80: 199-205.10.1016/j.ijrobp.2010.09.007Search in Google Scholar

Welsh J, Gomez D, Palmer MB, Riley BA, Mayankkumar AV, Komaki R, Dong L, et al. Intensity-modulated proton therapy further reduces normal tissue exposure during definitive therapy for locally advanced distal esophageal tumors: A dosimetric study. Int J Radiat Oncol Biol Phys 2011; 81: 1336-42.10.1016/j.ijrobp.2010.07.2001Search in Google Scholar

Lievens Y, Nulens A, Gaber MA, Defraene G, De Wever W, Stroobants S, et al. Intensity-modulated radiotherapy for locally advanced non-small-cell lung cancer: a dose-escalation planning study. Int J Radiat Oncol Biol Phys 2011; 80: 306-13.10.1016/j.ijrobp.2010.06.025Search in Google Scholar

Banu A, Enis O, Kaan G, Gungor G. Intensity modulated radiotherapy (IMRT) in bilateral retinoblastoma. Radiol Oncol 2010; 44: 194-8.Search in Google Scholar

Bailey DW, Lalith K; Podgorsak MB. A fully electronic intensity-modulated radiation therapy quality assurance (IMRT) process implemented in a network comprised of independent treatment planning, record and verify, and delivery systems. Radiol Oncol 2010; 44: 124-30.Search in Google Scholar

Śladowska A, Hetnał M, Dymek P, Kabat D, Kisielewicz K, Wawrzak M, et al. Application of IMRT in adjuvant treatment of soft tissue sarcomas of the thigh - preliminary results. Reports of Practical Oncology and Radiotherapy 2011; 16: 110-4.10.1016/j.rpor.2011.02.006Search in Google Scholar

Weisenburger DD, DeGowin RL, Gibson P, Armitage JO. Remission of giant lymph node hyperplasia with anemia after radiotherapy. Cancer 1979; 44: 457-62.10.1002/1097-0142(197908)44:2<457::AID-CNCR2820440212>3.0.CO;2-4Search in Google Scholar

Nordstrom DG, Tewfik HH, Latourette HB. Plasma cell giant lymph node hyperplasia responding to radiation therapy. AJR Am J Roentgenol 1978; 130: 169-71.10.2214/ajr.130.1.169Search in Google Scholar

Marti S, Pahissa A, Guardia J, Moragas A, Bacardi R. Multicentric giant follicular lymph node hyperplasia. Favorable response to radiotherapy. Cancer 1983; 51: 808-10.10.1002/1097-0142(19830301)51:5<808::AID-CNCR2820510510>3.0.CO;2-5Search in Google Scholar

Veldhuis GJ, van der Leest AH, de Wolf JT, de Vries EG, Vellenga E. A case of localized Castleman's disease with systemic involvement: treatment and pathogenetic aspects. Ann Hematol 1996; 73: 47-50.10.1007/s002770050201Search in Google Scholar

Beck JT, Hsu SM, Wijdenes J, Bataille R, Klein B, Vesole D, et al. Brief report: alleviation of systemic manifestations of Castleman's disease by monoclonal anti-interleukin-6 antibody. N Engl J Med 1994; 330: 602-5.10.1056/NEJM199403033300904Search in Google Scholar

Li X, Wang X, Li Y, Zhang X. A 4D IMRT planning method using deformable image registration to improve normal tissue sparing with contemporary delivery techniques. Radiat Oncol 2011; 6: 83.10.1186/1748-717X-6-83Search in Google Scholar

Chapet O, Fraass BA, Ten Haken RK. Multiple fields may offer better esophagus sparing without increased probability of lung toxicity in optimized IMRT of lung tumors. Int J Radiat Oncol Biol Phys 2006; 65: 255-65.10.1016/j.ijrobp.2005.12.028Search in Google Scholar

Suciu D. Cellular death by apoptosis in some radiosensitive and radioresistant mammalian tissues. J Theor Biol 1983; 105: 391-401.10.1016/0022-5193(83)90183-2Search in Google Scholar